• 1
    Åkesson P, Sjöholm AG, Björck L. Protein SIC, a novel extracellular protein of Streptococcus pyogenes interfering with complement function. J Biol Chem 1996; 271 : 10818.
  • 2
    Fernie-King BA, Seilly DJ, Willers C, Würzner R, Davies A, Lachmann PJ. Streptococcal inhibitor of complement (SIC) inhibits the membrane attack complex by preventing uptake of C567 onto cell membranes. Immunol 2001; 103 : 3908.
  • 3
    Fernie-King BA, Seilly DJ, Davies A, Lachmann PJ. Streptococcal Inhibitor of Complement (SIC) inhibits two further components of the mucosal innate immune system: secretory leucokyte proteinase inhibitor (SLPI) and lysozyme. Infect Immun 2002; 70 : 490816.
  • 4
    Frick I-M, Åkesson P, Rasmussen M, Schmidtchen A, Björck L. SIC—a secreted protein of Streptococcus pyogenes that inactivates antibacterial peptides. J Biol Chem 2003; 278 : 165616.
  • 5
    Lukomski S, Hoe NP, Abdi I et al. Nonpolar inactivation of the hypervariable Streptococcal Inhibitor of Complement gene (sic) in serotype M1 Streptococcus pyogenes significantly decreases mouse mucosal colonisation. Infect Immun 2000; 68 : 53542.
  • 6
    Hoe NP, Ireland RM, DeLeo FR et al. Insight into the molecular basis of pathogen abundance: Group A Streptococcus inhibitor of complement inhibits bacterial adherence and internalization into human cells. PNAS 2002; 99 : 764651.
  • 7
    Hoe NP, Kordari P, Cole R et al. Human immune response to Streptococcal Inhibitor of Complement, a serotype M1 Group A Streptococcus extracellular protein involved in epidemics. J Infect Dis 2000; 182 : 142536.
  • 8
    Hoe NP, Vuopio-Varkila J, Vaara M et al. Distribution of Streptococcal Inhibitor of Complement variants in pharyngitis and invasive isolates in an epidemic of serotype M1 Group A Streptococcus infections. J Infect Dis 2001; 183 : 6339.
  • 9
    Diamond G, Legarda D, Ryan LK. The innate immune response of the respiratory epithelium. Immunol Rev 2000; 173 : 2738.
  • 10
    Dinulos JGH, Mentele L, Fredericks P, Dale BA, Darmstadt G. Keratinocyte expression of human β-defensin 2 following bacterial infection: role in cutaneous host defense. Clin Diagn Lab Immunol 2003; 10 : 1616.
  • 11
    Harder J, Bartels J, Christophers E, Schröder J-M. Isolation and characterisation of human β-defensin 3, a novel human inducible peptide antibiotic. J Biol Chem 2001; 276 : 570713.
  • 12
    Schutte BC, McCray Jr.PB. β-defensins in lung host defense. Ann Rev Physiol 2002; 64 : 70948.
  • 13
    Schibli DJ, Hunter HN, Aseyev V et al. The solution structures of the human β-defensins lead to a better understanding of the potent bactericidal activity of hBD-3 against Staphylococcus aureus. J Biol Chem 2002; 277 : 827989.
  • 14
    Mathews M, Jia HP, Guthmiller JM, Losh G, Graham S, Johnson GK, Tack BF, McCray Jr. PB. Production of β-defensin antimicrobial peptides by the oral mucosa and salivary glands. Infect Immun 1999; 67 : 27405.
  • 15
    Humphrey SP, Williamson RT. A review of saliva: normal composition, flow, and function. J Prosthet Dent 2001; 85 : 1629.
  • 16
    Travis SM, Anderson NN, Forsyth WR et al. Bactericidal activity of mammalian cathelicidin-derived peptides. Inf Imm 2000; 68 : 274855.
  • 17
    Reid SD, Hoe NP, Smoot LM, Musser JM. Group A Streptococcus: allelic variation, population genetics, and host–pathogen interactions. J Clin Invest 2001; 107 : 3939.